Table 1.
Baseline characteristics of the study population
| Variables | Value | Variables | Value |
|---|---|---|---|
| Age, years | 67 ± 12 | LVEDD, mm | 64.2 ± 8.3 |
| Male, % | 57 | LVESD, mm | 53.5 ± 9.2 |
| Smoking, % | 12 | LVEDV, ml | 152 ± 57 |
| Hypertension, % | 38 | LVESV, ml | 109 ± 45 |
| Diabetes, % | 23 | EF, % | 27 ± 10 |
| BMI | 24.5 ± 4.2 | Glucose, mg/dl | 115 ± 46 |
| AF, % | 64 | BUN, mg/dl | 29 ± 9 |
| Etiology of HF | Creatinine, mg/dl | 1 ± 0.22 | |
| Ischemic, % | 52 | Hemoglobin, g/dl | 12.8 ± 2 |
| Valvular, % | 13 | WBC × 103/µl | 8 ± 1.8 |
| DCMP, % | 35 | P count × 103/µl | 213 ± 65 |
| Medications | Sodium, mEq/l | 136 ± 4.3 | |
| ACE inhibitors, % | 66 | Potassium, mEq/l | 4.5 ± 0.68 |
| β-Blocker, % | 40 | MPO, ng/ml | 255 ± 227 |
| Digoxin, % | 28 | H-FABP, ng/ml | 60.6 ± 48.5 |
| Diuretics, % | 70 | TnT, ng/ml | 0.07 ± 0.15 |
Values represent means ± SD unless otherwise stated. ACE = Angiotensin-converting enzyme; AF = atrial fibrillation; BMI = body mass index; DCMP = dilated cardiomyopathy; LVEDD = LV end-diastolic diameter; LVEDV = LV end-diastolic volume; LVESD = LV end-systolic diameter; LVESV = LV end-systolic volume; P = platelet; WBC = white blood count.